Industry

FDA Approves Opus Genetics’ Phentolamine Ophthalmic Solution 0.75% to Treat Presbyopia

Vision Monday1d ago1 min read

RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc., a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced that the United States Food and Drug Administration (FDA) has granted approval for phentolamine ophthalmic solution 0.75% for the treatment of age-related presbyopia in adults. This approval expands the indication for the product, which has been marketed in the U.S. as RYZUMVI for the treatment of pharmacologically induced mydriasis.

Read full article on Vision Monday

AI Summary

Quick Take

The FDA has approved Opus Genetics’ phentolamine ophthalmic solution 0.75% for the treatment of age-related presbyopia in adults. This approval expands the indication for the drug, which is already commercially available in the U.S. under the brand name RYZUMVI for the reversal of pharmacologically induced mydriasis.

Why It Matters

This approval introduces a new pharmacological player into the competitive presbyopia market, offering a non-surgical alternative for patients looking to manage near-vision loss. As an alpha-adrenergic antagonist, phentolamine provides a different mechanism for pupil modulation compared to traditional cholinergic miotics. For eye care providers, this represents a versatile therapeutic that many may already be familiar with for in-office pupil reversal, now transitioned into a daily-use prescription for adult presbyopes.

Key Details

The FDA approval specifically covers phentolamine ophthalmic solution 0.75% for adult patients with age-related presbyopia.
The solution is currently marketed in the United States as RYZUMVI.
Previously, the drug's sole indication was for the treatment of pharmacologically induced mydriasis (reversing diagnostic dilation).
Opus Genetics, the manufacturer, is a clinical-stage biopharmaceutical company that also specializes in gene therapies for inherited retinal diseases.

Practice Implications

Clinicians now have an additional FDA-approved drop to discuss with presbyopic patients who wish to reduce their reliance on reading glasses. Given that the medication is already used in clinical settings for mydriasis reversal, practitioners may find the safety and tolerability profile easier to communicate to patients transitioning to daily therapeutic use.

Who's Affected

OptometristsOphthalmologistsComprehensive Eye Care ProvidersPresbyopic Patients

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.